Neuropathix, Inc. is a drug discovery company with globally patented anti-inflammatory technology. Our lead compound KLS-13019, is a first-in-class, non-opioid, non-NSAID that has been validated through IND enabling studies to prevent and reverse chemotherapy induced peripheral neuropathy (CIPN). Preclinical animal studies to date indicate KLS-13019’s ground-breaking potential in treating neuro-inflammation, neuropathic pain, and opioid use disorder. In addition to our drug’s ability to reverse neuropathic pain, animal studies have shown KLS-13019’s ability to reduce morphine reward seeking (addiction), and withdrawal symptoms (aggression and anxiety) caused by the use of naloxone after chronic morphine dosing.